Journal article
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Abstract
BACKGROUND AND PURPOSE: The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously.
METHODS: We analyzed the subtypes of cerebrovascular events in 21 105 patients participating in …
Authors
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM
Journal
Stroke, Vol. 45, No. 8, pp. 2372–2378
Publisher
Wolters Kluwer
Publication Date
8 2014
DOI
10.1161/strokeaha.114.006025
ISSN
0039-2499